Drug intelligence / Profile preview

SD-A05

Development stage: Preclinical
Lead developer: Sinedore Medicine
Modality: Peptides

Overview

SD-A05 is a dual-agonist peptide targeting the glucagon-like peptide-1 (GLP-1) and gastric inhibitory polypeptide (GIP) receptors, currently under preclinical development by Sinedore Medicine for the treatment of obesity. As a unimolecular dual incretin receptor agonist, it is designed to leverage the synergistic effects of GLP-1 and GIP signaling to enhance weight loss through appetite suppression, delayed gastric emptying, and improved metabolic regulation. The candidate aims to provide a potent therapeutic option for weight management by mimicking the action of these two key metabolic hormones.

Targets

GLP1R (GLP-1R)GIPR (Gastric inhibitory polypeptide receptor)

Beyond the preview

Go deeper on SD-A05.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SD-A05.

Explore the full profile